FXYD3 and neoplasm: The results demonstrated that the combination of FXYD3@PEP with gemcitabine and cisplatin exerted a more pronounced antitumor effect than FXYD3@PEP alone or gemcitabine and cisplatin combination therapy in nude mice and spontaneous tumor formation mouse models (Figure 9H–K).